Allegra Rollo

MD Candidate @BrownMedicine via @HarvardHEB and gyn onc consulting. Tweets are my own.

[Allegra Rollo @AllegraRollo]

This week on Spotify I discuss the rapidly evolving gyn onc therapeutic landscape, providing a recap on ADC approvals, new PARPi data, and exciting frontline IO results! Episode available here: https://t.co/KNNXvny47s #gyncsm #ovariancancer #cervicalcancer #endometrialcancer

[Columbia Urology @ColumbiaUrology]

Superb finish to our visiting #urology sub-intern season. Our residents & faculty always enjoy learning from these impressive scholars!

Derek Tran @ZuckerSoM @SmithInstUro

Joseph Piccolo @GUUrology

@AllegraRollo @BrownUrology

@myles__reed @WCMUrology

[Wai Lee @Mrwailee]

Evening hangout with the cool kids from @WCMUrology& @ColumbiaUrology

Thank you @MDTPelvicHealth for the great time and teaching us about #altaviva

[Columbia Urology @ColumbiaUrology]

Interstitial Cystitis / Bladder Pain Syndrome is devastating and can be very challenging to treat.

We were so fortunate to have world-renown expert on #icbps Dr Robert M Moldwin @SmithInstUro speak to us about tailoring tx by phenotype & advancing the paradigm.

👏 👏

[Allegra Rollo @AllegraRollo]

Honored to contribute to the conversation on reproductive medicine in the military with @eadashi in @FertStert. Infertility among those who serve for our country deserves the same clinical rigor and policy attention we give other health crises. #TRICARE https://t.co/L8sHukfsas

[Brown Urology @BrownUrology]

94th Annual New England Section of AUA

Great job Brown Urology

[Wafik S. El-Deiry, MD, PhD, FACP @weldeiry]

Attending @BrownMedicine #AMS_CRJC led today by medical students Ege Gungor Onal, @AllegraRollo, and Valeria Brown

Presentations by medical student Jacob Licht on pioneer factors like Brn2 that he got interested in during two years of research at @theNCI in the Yawen Bai Lab

Good review: “Pioneer factors: roles and their regulation in development”
https://t.co/yiQQ0dAj87

Allegra gave an interesting presentation about pharma R&D relationships with drug costs

@BrownUniversity @BrownUCancer #LegorretaCancerCenter
@LifespanHlthSys @RIHospital @MiriamHospital @carenewengland @HasbroChildrens

[Wafik S. El-Deiry, MD, PhD, FACP @weldeiry]

Attending @BrownMedicine #AMS_CRJC led today by medical students Ege Gungor Onal, @AllegraRollo, James He and Valeria Brown

Presentation by Valeria Brown on TAp63 represses transcription of MYCN/NCYM gene and its high levels of expression are associated with favorable outcome in neuroblastoma

https://t.co/xRl2ODW7aq

Learning about NCYM and MYCN regulation by TAp63, trying to understand how this repression works as well as ATRA effects. Some interesting findings with significant limitations. Great discussions about TMZ and p63 and combos in different tumor types.

@BrownUniversity @BrownUCancer #LegorretaCancerCenter
@LifespanHlthSys @RIHospital @MiriamHospital @carenewengland @HasbroChildrens

[Wafik S. El-Deiry, MD, PhD, FACP @weldeiry]

Attending @BrownMedicine #AMS_CRJC led today by medical students Ege Gungor Onal, @AllegraRollo, and Valeria Brown

Presentation by @AllegraRollo on RCT’s in cancer medicine. Great presentation and discussion.

@BrownUniversity @BrownUCancer #LegorretaCancerCenter
@LifespanHlthSys @RIHospital @MiriamHospital @carenewengland

[Wafik S. El-Deiry, MD, PhD, FACP @weldeiry]

Attending @BrownMedicine #AMS_CRJC led today by medical students Ege Gungor Onal, @AllegraRollo, and Valeria Brown

Presentation today by Ege Gungor Onal

A vaccine targeting resistant tumours by dual T cell plus NK cell attack

https://t.co/2ym4NxGd5k

From lab of Dr. Kai Wucherpfennig at @DanaFarber

@BrownUniversity @BrownUCancer #LegorretaCancerCenter
@LifespanHlthSys @RIHospital @MiriamHospital @carenewengland

[Allegra Rollo @AllegraRollo]

Incredible seeing positive topline results for DUO-O, the first IO + PARPi trial to readout in #ovariancancer! Will be interesting to compare efficacy in durvalumab + olaparib vs. durva arms - what will be magnitude of benefit of IO + PARPi, given past IO failures in OC? #gyncsm

[Allegra Rollo @AllegraRollo]

Amazing to see GY018 and RUBY change SOC in #endometrialcancer! Comparable dMMR PFS data. Keep in mind... RUBY not powered for pMMR PFS. GY018 tx given for 21 mos., RUBY tx for 3 yrs. GY018 larger n size. RUBY great OS ITT data (not yet stat signif)... Incredible! #SGOMtg #gyncsm

[Allegra Rollo @AllegraRollo]

After neoadjuvant talazoparib results in BRCAm BC (Litton J.K. 2017), neoadjuvant olaparib in #ovariancancer (with mutation in BRCA1/2, RAD51C/D, or PALB2) by @ShannonWestin shows outstanding surgical outcomes after only 2 cycles of olaparib, even in Stage IV pts #SGOMTG #SGO2023

[Allegra Rollo @AllegraRollo]

Check out my latest white paper on the amazing therapeutic advances that gyn onc saw in 2022, from PARPi data and the accelerated approval of the first ADC in #ovariancancer to impressive IO + chemo results from the RUBY trial in #endometrialcancer #gyncsm https://t.co/CvfWBkgktZ

[Allegra Rollo @AllegraRollo]

Citing examples from metastatic melanoma, chronic myeloid leukemia, and ovarian cancer, an interesting article from @DrMaurieMarkman on how Overall Survival is an important but not always straightforward endpoint in randomized #oncology trials https://t.co/2ld7eyBrJV #gyncsm

[Allegra Rollo @AllegraRollo]

Discussant: OS in NORA, NOVA, ARIEL-3 should be taken as exploratory endpt. PFS, PFS2, & TSST are sufficient for clinical decisions + support use of PARPi in 2L maint. regardless of BRCA status. EMA views OS results holistically + will not restrict 2L maint. PARPi labels #gyncsm

[Allegra Rollo @AllegraRollo]

Analysis of NORA (APAC) conducted at 44% maturity showed that ISD of niraparib maint. in PSOC led to favorable OS trends across ITT, BRCAm, and non-BRCAm, despite 43% of pbo pts crossing over to PARPi! Final prespecified OS analysis expected in 2023 #ovariancancer #ESMO22 #gyncsm

[Allegra Rollo @AllegraRollo]

#Immunogen's mirvetuximab just became first ADC to be approved in #ovariancancer (platinum-resistant) based on SORAYA! NCCN compendia listings are expected for monotherapy in late-22 and in combo with bev in early-23. Data from confirmatory MIRASOL expected in early-23 #gyncsm

[Allegra Rollo @AllegraRollo]

Failure of IO in LACC from CALLA trial gives pause to whether tx plan is the correct approach (RT may be immunosuppressive according to timing, dose, fractioning). Worth exploring neoadjuvant instead of adjuvant IO in LACC #cervicalcancer #IGCS2022 #gyncsm

[Allegra Rollo @AllegraRollo]

ASCO publishes updated PARPi recommendations in #ovariancancer. Correction needed: Figure A2 in appendix should have contained HRD+ status in olaparib + bev maintenance recommendation based on PAOLA-1 label @JCO_ASCO @AstraZenecaUS #gyncsm https://t.co/XE50uVx4xY